-
Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan
Monday, April 12, 2021 - 12:48pm | 282The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous Pemphigoid (BP), allowing clinical sites to open mid-2021, subject...
-
Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally
Monday, December 12, 2016 - 9:51am | 917Shares of Immune Pharmaceuticals Inc (NASDAQ: IMNP) were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company. Shares have given up most of the gains on Thursday trading....